arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


Disclaimer: CME certification for these activities has expired. All information is pertinent to the timeframe in which it was released.


New Evidence-Based Approaches in Bipolar Disorder and Schizophrenia


GOAL
To update the practicing psychiatrist on the diagnostic complexity and current treatment advances in bipolar disorder.

TARGET AUDIENCE
This activity is designed for psychiatrists. No prerequisites required.

LEARNING OBJECTIVES
The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. At the conclusion of this activity, participants should be able to:

  • Evaluate methods to optimize pharmacologic interventions and translate switching strategies into improved patient functioning.
  • Recognize a maintenance approach versus a recovery approach in the treatment of individuals with serious psychiatric disorders.
  • Review practice guideline considerations and recommendations when treating individuals with serious psychiatric disorders.

ACCREDITATION STATEMENT
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. The estimated time to complete this educational activity: 2 hours.

Release date: March 15, 2005. Expiration date: March 15, 2007.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

This program is supported by an educational grant from Pfizer Inc.

Full Disclosure Policy Affecting CME Activities:
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of Johns Hopkins University School of Medicine to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Program Director and Participating Faculty reported the following:

PROGRAM DIRECTOR

Glenn Treisman, MD
Associate Professor
Department of Psychiatry and Behavioral Sciences
The Johns Hopkins University School of Medicine
Baltimore, Maryland
Dr Treisman reports having no financial or advisory relationships with corporate organizations related to this activity.

PARTICIPATING FACULTY

David G. Daniel, MD
President, Bioniche Development, Inc.
Clinical Professor
Psychiatry and Behavioral Sciences
George Washington University
Washington, DC
Dr Daniel reports receiving grants/research support from Abbott Laboratories, Bristol-Myers Squibb Company, and Pfizer Inc; serving as a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Pfizer Inc, and Sumitomo; and receiving honoraria from Abbott Laboratories, Bristol-Myers Squibb Company, and Pfizer Inc.

Nabil Kotbi, MD
Resident in Psychiatry
Department of Psychiatry
SUNY Downstate Medical Center
Brooklyn, New York
Dr Kotbi reports having no financial or advisory relationships with corporate organizations related to this activity.

Peter J. Weiden, MD
Professor of Psychiatry
Department of Psychiatry
SUNY Downstate Medical Center
Brooklyn, New York
Dr Weiden reports receiving grants/research support from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Pharmaceutica, and Pfizer Inc; serving as a consultant for AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Pharmaceutica, Organon, and Pfizer Inc; and receiving honoraria from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Com-pany, Janssen Pharmaceutica, and Pfizer Inc.

Notice:The audience is advised that an article in this CME activity contains reference(s) to unlabeled or unapproved uses of drugs or devices.

Dr Daniel—ziprasidone.

All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or devices.

Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.





Johns Hopkins Advanced Studies in Medicine (ISSN-1558-0334), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.